Two types of engineered T cells have been successfully used to treat cancer patients, one with an antigen recognition domain derived from antibodies (chimeric antigen receptors, CARs) and the other de
Cytokines augment T cell function, but the nature of the optimal signals are not well defined. We deployed orthogonal cytokine-receptors to diversify the JAK/STAT signaling profiles elicited by orthog
